BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Medicine by Design - ECPv6.15.18//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Medicine by Design
X-ORIGINAL-URL:https://mbd.ccrm.ca
X-WR-CALDESC:Events for Medicine by Design
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Toronto
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20200308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20201101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20210314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20211107T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20220313T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20221106T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20230312T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20231105T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20240310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20241103T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20260308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20261101T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20250422T120000
DTEND;TZID=America/Toronto:20250422T130000
DTSTAMP:20260405T130403
CREATED:20240416T192233Z
LAST-MODIFIED:20250401T182418Z
UID:33777-1745323200-1745326800@mbd.ccrm.ca
SUMMARY:Global Speaker Series: Karen Hirschi\, PhD - University of Virginia School of Medicine
DESCRIPTION:The Medicine by Design Global Speaker Series invites established and emerging international leaders in regenerative medicine to engage with our extraordinary community of researchers and clinicians. \nMedicine by Design is pleased to welcome Karen Hirschi\, PhD\, for a talk titled\, ‘Regulation of Endothelial Specialization in Development and Disease.’ \nKaren Hirschi is an Alumni Professor of Cell Biology\, University of Virginia School of Medicine\, Director\, UVA Developmental Genomics Center\, Associate Director for Scientific Programs\, UVA Medical Scientist Training Program\, and Adjunct Professor\, Yale University School of Medicine & Baylor College of Medicine. \nThis event will be held at the Terrence Donnelly Centre for Cellular & Biomolecular Research\, Red Room. \nRegister here\n\n \nAbout Karen Hirschi\nKaren K. Hirschi received an Honors BS at Pennsylvania State University and PhD in Nutritional Biochemistry at the University of Arizona. She did her postdoctoral training in vascular cell and developmental biology at Harvard Medical School\, and began her first tenure-track faculty position at Baylor College of Medicine\, where she became a tenured Professor and was the founding Deputy Director of the Stem Cell and Regenerative Medicine Center. Dr. Hirschi moved to Yale University School of Medicine\, where she served as a Professor in the Departments of Medicine and Genetics and as a Co-Director of the Cardiovascular Research Center. Her lab is currently at University of Virginia School of Medicine\, where she serves as the Alumni Professor of Cell Biology and founding Director of the Developmental Genomics Center that focuses on identifying genetic mutations that cause developmental disorders. The Hirschi lab is primarily interested in vascular development and focuses on elucidating regulators of endothelial cell differentiation and specialization\, as well as modulators of endothelial cell proliferation during vessel formation. They use the mouse model system to study the regulation of these processes in vivo. Insights gained are applied to the modulation of the commitment of pluripotent human stem cells toward vascular cell fates\, and to the genesis and optimization of clinically relevant strategies to promote endogenous vascular regeneration and repair in disease conditions.
URL:https://mbd.ccrm.ca/event/global-speaker-series-karen-hirschi/
LOCATION:Donnelly Centre for Cellular and Biomolecular Research\, Red Room\, 160 College Street\, Toronto\, Ontario\, M5S 3E1\, Canada
CATEGORIES:Global Speaker Series
ORGANIZER;CN="Medicine by Design":MAILTO:info.mbd@utoronto.ca
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20250304T120000
DTEND;TZID=America/Toronto:20250304T130000
DTSTAMP:20260405T130403
CREATED:20241024T142418Z
LAST-MODIFIED:20250225T161919Z
UID:34708-1741089600-1741093200@mbd.ccrm.ca
SUMMARY:Global Speaker Series: Lorenz Studer\, MD - Memorial Sloan-Kettering Cancer Center
DESCRIPTION:The Medicine by Design Global Speaker Series invites established and emerging international leaders in regenerative medicine to engage with our extraordinary community of researchers and clinicians. \nMedicine by Design is pleased to welcome\, Lorenz Studer\, MD\, Director\, Center for Stem Cell Biology\, Memorial Sloan-Kettering Cancer Center. \nTalk title: Applications of human PSCs in modeling and treating neural disease \nThis event will be held in-person only at the Terrence Donnelly Centre for Cellular & Biomolecular Research\, Red Room. \nREGISTER HERE\nAbout Lorenz Studer \n\nLorenz Studer investigates human stem cells as tools to understand normal and pathological development in the nervous system and to develop cell-based therapies.  \nHis interest in medicine began when he was about 18. He had been in the hospital himself for an unusual type of bone infection and had also lost several close relatives to cancer. He decided to go to medical school\, spending my first two years at the University of Fribourg and the latter four at the University of Bern. There\, he met Christian Spenger\, a neurosurgery fellow who thought we might be able to treat Parkinson’s disease in animals by implanting fetal tissue to yield healthy new brain cells. This idea of replacing damaged brain cells seemed revolutionary to him. \nAfter he earned my MD degree in 1991\, Christian and he set up a laboratory at the University of Bern. We were given a room that had been used to store brooms. But it was a good size\, and they managed to get funding for the resources they needed. \nThey began tissue culture studies and developed ways to ensure quality control of the animal fetal tissue cells. He developed an assay to measure the cells’ ability to produce dopamine — the chemical whose deficiency causes the symptoms of Parkinson’s. They also studied the effects of proteins necessary for the growth of specific brain cells. Their early work culminated in 1995\, when they implanted human fetal nerve cells into a Parkinson’s patient. \nTalk abstract \nHuman pluripotent stem cells (hPSCs) present a powerful tool for studying human disease and for developing novel cell-based therapies in regenerative medicine. Our group has developed strategies to coax human PSCs into many specific neuron subtypes on demand and at scale. For some lineages\, such as midbrain dopamine neurons\, those efforts have recently translated into a first-in-human clinical trial using clinical grade\, “off-the-shelf” dopamine neurons for treating patients with advanced Parkinson’s disease (PD). I will provide an update on the results from this trial and discuss some of the next steps and potential next generation products in PD cell therapy development. \nI will further discuss recent progress in the lab on chemical and genetic strategies to drive neuronal maturation and aging in human PSC-derived neural cells type that enable improved modeling neural disorders including neurodegenerative disease. Similarly\, new protocols enable the derivation of fast spiking PV+ cortical interneurons\, a neuronal cell type that has been very difficult to generate in past studies\, as PV marker expression and maturation occurs largely during postnatal development\, while hPSC-derived neurons typically capture fetal stages of neural development. Using hPSC-derived PV neurons we applied this protocol to study a set of structural variants highly associated with increased risk for schizophrenia development. This study enabled us to investigate novel interneuron-mediated defects that may be linked to aspects of neuropsychiatric disease. \n 
URL:https://mbd.ccrm.ca/event/global-speaker-series-lorenz-studer/
LOCATION:Donnelly Centre for Cellular and Biomolecular Research\, Red Room\, 160 College Street\, Toronto\, Ontario\, M5S 3E1\, Canada
CATEGORIES:Global Speaker Series
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20250225T120000
DTEND;TZID=America/Toronto:20250225T130000
DTSTAMP:20260405T130403
CREATED:20241001T173114Z
LAST-MODIFIED:20250211T192412Z
UID:34554-1740484800-1740488400@mbd.ccrm.ca
SUMMARY:Global Speaker Series: Glen Tibbits\, PhD - BC Children's Hospital Research Institute
DESCRIPTION:The Medicine by Design Global Speaker Series invites established and emerging international leaders in regenerative medicine to engage with our extraordinary community of researchers and clinicians. \nMedicine by Design is pleased to welcome\, Glen Tibbits\, PhD\, Distinguished Professor at Simon Fraser University and Co-Director of the Cellular and Regenerative Medicine Centre at the BC Children’s Hospital Research Institute. \nTalk title: Investigating inherited arrhythmias\, and cardiomyopathies using hiPSC-derived cardiomyocytes \nThis event will be held virtually only via Zoom. \nREGISTER HERE\nAbout Glen Tibbits \n\nAfter completing his Bachelor’s degree at McGill University\, Glen subsequently pursued graduate studies at the University of California\, Los Angeles. During his graduate studies at UCLA\, Glen developed a profound curiosity about the electrical and contractile properties of the heart while completing his MSc and PhD at the Brain Research Institute. With an American Heart Association Post-Doctoral Fellowship (PDF)\, he studied cardiac pharmacology in Niigata\, Japan in year one and cardiac biophysics at the UCLA School of Medicine in year two. He subsequently was appointed an Assistant Research Professor of Pediatric Cardiology at UCLA and then moved to Seattle\, WA to become an Assistant Professor at the University of Washington. When a faculty position opened at Simon Fraser University\, he chose to return to Canada after an absence of 15 years. At SFU he was appointed a Tier I Canada Research Chair in Molecular Cardiac Physiology from 2004-2018. The latter allowed him to start building a research program incorporating the use of human induced pluripotent stem cells differentiated into cardiomyocytes (hiPSC-CMs) to understand better inherited cardiac arrhythmias and cardiomyopathies\, more than a decade ago. In June 2024\, he was awarded a Distinguished Professorship at SFU. He is currently the Co-director of the Cellular and Regenerative Medicine Centre (CRMC) at the BC Children’s Hospital Research Institute which is a state-of-the-art facility for generating and phenotyping hiPSC-derived cardiomyocytes and pancreatic β cells.    \nTalk abstract \nAs Co-Director of the Cellular and Regenerative Medicine Centre (CRMC) at the BC Children’s Hospital Research Institute (BCCHR)\, we have been very fortunate to have the resources to build a state-of-the-art facility dedicated to the use of human induced pluripotent stem cell-derived cardiomyocytes (hiPSCCMs) to study cardiac diseases. While it is well established that a hiPSC-CM model offers distinct advantages in modeling cardiac disease and developing new therapies\, there can be limitations. The first part of this talk will address how the CRMC uses technology to overcome some of these disadvantages. The talk will then focus on using hiPSC-CM models to investigate inherited cardiac arrhythmias that can lead to sudden cardiac arrest (SCA). Genetic variants in cardiac ion channels can cause channel dysfunction or channelopathies\, and hiPSC-CM models have been insightful in investigating the mechanisms of these diseases. However\, the leading known cause of sudden cardiac arrest in youth and elite athletes is hypertrophic cardiomyopathy (HCM) which is generally caused by genetic variants of sarcomeric proteins such as the myosin heavy chain and the troponin complex. Exploring the mechanisms of these diseases and discovering improved therapeutics using hiPSC-CMs will be an important focus of the talk.
URL:https://mbd.ccrm.ca/event/global-speaker-series-glen-tibbits/
LOCATION:Ontario
CATEGORIES:Global Speaker Series
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20250121T120000
DTEND;TZID=America/Toronto:20250121T130000
DTSTAMP:20260405T130403
CREATED:20241001T172632Z
LAST-MODIFIED:20241121T171053Z
UID:34550-1737460800-1737464400@mbd.ccrm.ca
SUMMARY:Global Speaker Series: Juan Melero-Martin\, PhD - Boston Children's Hospital\, Harvard Medical School
DESCRIPTION:The Medicine by Design Global Speaker Series invites established and emerging international leaders in regenerative medicine to engage with our extraordinary community of researchers and clinicians. \nMedicine by Design\, is pleased to welcome\, Juan Melero-Martin\, PhD. Dr. Melero-Martin is an Associate Professor of Surgery at Harvard Medical School\, a principal faculty at the Harvard Stem Cell Institute\, and the inaugural incumbent of an endowed Chair in Cardiac Surgery at Boston Children’s Hospital.  \nTalk title: Advancing Vascularization Strategies in Regenerative Medicine \nThis event will be held in-person only at the Terrence Donnelly Centre for Cellular & Biomolecular Research\, Red Room. \nREGISTER HERE\nAbout Juan Melero-Martin \n\nDr. Melero-Martin graduated in Chemical Engineering from the University of Seville\, Spain\, in 1998. After working for three years in Industry\, he earned a Ph.D. in Biochemical Engineering from the University of Birmingham\, UK\, in 2005. He then trained as a post-doctoral fellow in the Vascular Biology Program at Boston Children’s Hospital. In 2008\, he joined the Department of Cardiac Surgery at Boston Children’s Hospital to run a biomedical research laboratory. Currently\, he is an Associate Professor of Surgery at Harvard Medical School\, a principal faculty at the Harvard Stem Cell Institute\, and the inaugural incumbent of an endowed Chair in Cardiac Surgery at Boston Children’s Hospital.  \nDr. Melero-Martin’s research interest is primarily centered on bioengineering blood vessels. He investigates how vascular networks are formed from stem cell differentiation and has developed novel bioengineering applications with clinical translational potential. Dr. Melero-Martin strives to investigate questions that can have a long-lasting impact on regenerative medicine. His research goals are divided into four general categories:  \n\nTherapeutic revascularization of ischemic tissues (i.e.\, vascular cell therapy). \nEngineering organ-specific vascular niches for tissue regeneration. \nGenetically engineering vascular networks for drug delivery.  \nVascularization of organoid systems.  \n\nDr. Melero-Martin’s laboratory is a reference in human progenitor and pluripotent stem cell-derived vascular cells\, areas in which he has contributed multiple original papers. His group has developed novel approaches to bioengineer vascular networks and has shown that bioengineered vascular networks can be used to harness the regenerative potential of other stem cells. In addition\, his group developed a model that uses genetically engineered blood vessels to achieve the controlled release of therapeutic proteins in vivo.  \nDr. Melero-Martin routinely collaborates and provides expertise to other laboratories in the US and abroad. People from other groups continue to come to his laboratory to learn about stem cell-derived vascular cells and models for building blood vessels. Dr. Melero-Martin has a track record of successfully obtaining funds from multiple sources\, including the NIH\, the private sector\, foundations\, and intramural support. The NIH has continuously funded his research since 2009.  
URL:https://mbd.ccrm.ca/event/global-speaker-series-juan/
LOCATION:Donnelly Centre for Cellular and Biomolecular Research\, Red Room\, 160 College Street\, Toronto\, Ontario\, M5S 3E1\, Canada
CATEGORIES:Global Speaker Series
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20241107T110000
DTEND;TZID=America/Toronto:20241107T120000
DTSTAMP:20260405T130403
CREATED:20241001T172231Z
LAST-MODIFIED:20241015T193636Z
UID:34548-1730977200-1730980800@mbd.ccrm.ca
SUMMARY:Global Speaker Series: Emily R. Miraldi\, PhD - Cincinnati Children's Hospital Medical Center
DESCRIPTION:The Medicine by Design Global Speaker Series invites established and emerging international leaders in regenerative medicine to engage with our extraordinary community of researchers and clinicians. \nMedicine by Design\, is pleased to welcome\, Emily R. Miraldi\, PhD. Dr. Miraldi is an Associate Professor of Immunobiology and Biomedical Informatics at the Cincinnati Children’s Hospital Medical Center. \nTalk title: “Inference of gene regulatory mechanisms from scRNA-seq and scATAC-seq” \nThis event will be held in-person only at the Terrence Donnelly Centre for Cellular & Biomolecular Research\, Red Room as well as virtually. \nThis event is co-sponsored by the Donnelly Centre for Cellular & Biomolecular Research. \n\n  \nREGISTER HERE\nAbout Emily R. Miraldi \n\nDr. Miraldi is an Associate Professor of Immunobiology and Biomedical Informatics at the Cincinnati Children’s Hospital Medical Center. \nHer lab’s research goal is immuno-engineering: to alter the behavior of specific immune cell populations in disease contexts (autoimmune disease\, organ transplant\, and cancer) without compromising the body’s homeostatic immune function (e.g. defense against pathogens). Thus\, it is critical to develop a nuanced understanding of how different immune cells sense and respond to environmental cues across the body\, in both physiological and disease settings. To this end\, her lab’s major focus is reverse-engineering the underlying logic of immune cells (molecular networks that drive cellular responses) from high-dimensional molecular measurements of immune cells in action (sensing and responding to perturbations\, disease conditions\, etc.). \nThe lab’s focus is transcriptional regulatory network inference\, modeling gene expression as a function of transcription factor activities\, from gene expression and measurements of chromatin state. Chromatin accessibility measurements by ATAC-seq\, together with transcription-factor DNA-binding preferences (motifs)\, can be used to broadly profile potential transcription factor binding events in relatively small populations of cells. Thus\, we have used ATAC-seq with RNA-seq to enable de novo inference of transcriptional regulatory networks in physiological settings where sample material is limiting (e.g.\, intestinal immune cells in response to microbial/genetic perturbations). To date\, most of these efforts have been in mouse models\, as it is generally not possible to obtain sufficient sample material for similar experimental designs in human. To build human immune cell models\, we are developing multi-task learning approaches to leverage evolutionarily conserved relationships and borrow statistical power from mouse datasets for inference in human. We are also developing methods to enable transcriptional regulatory network inference in very rare cell populations\, as measured from single-cell RNA-seq experiments.
URL:https://mbd.ccrm.ca/event/global-speaker-series-emily-miraldi/
LOCATION:Donnelly Centre for Cellular and Biomolecular Research\, Red Room\, 160 College Street\, Toronto\, Ontario\, M5S 3E1\, Canada
CATEGORIES:Global Speaker Series
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20241007T120000
DTEND;TZID=America/Toronto:20241007T130000
DTSTAMP:20260405T130403
CREATED:20240416T192016Z
LAST-MODIFIED:20240808T132739Z
UID:33775-1728302400-1728306000@mbd.ccrm.ca
SUMMARY:Global Speaker Series: Robert Signer\, PhD - University of California\, San Diego
DESCRIPTION:The Medicine by Design Global Speaker Series invites established and emerging international leaders in regenerative medicine to engage with our extraordinary community of researchers and clinicians. \nMedicine by Design\, in partnership with the McEwen Stem Cell Institute\, is pleased to welcome Robert Signer\, PhD. Dr. Signer is Deputy Director of the Stem Cell Discovery Center and an Associate Professor of Medicine in the Division of Regenerative Medicine at the University of California San Diego. \nHosted by Medicine by Design\, in partnership with the McEwen Stem Cell Institute.  \nTalk title: “Stem Cell Fitness & Longevity: The Role of Proteostasis”  \nThis event will be held in-person only at the Terrence Donnelly Centre for Cellular & Biomolecular Research\, Red Room. \nREGISTER HERE\nAbout Robert Signer \n\nDr. Robert Signer is a stem cell biologist whose trailblazing work on protein synthesis and homeostasis in blood-forming stem cells opened the door to unchartered areas of cellular investigation. Dr. Signer is currently the Deputy Director of the Sanford Stem Cell Discovery Center and an Associate Professor of Medicine in the Division of Regenerative Medicine at UC San Diego.  \nPreviously\, Dr. Signer trained as a Postdoctoral Fellow at the UT Southwestern Medical Center. He earned a Ph.D. in Cellular and Molecular Pathology at UCLA\, and a Bachelor’s in Engineering Science from the University of Toronto. His discoveries have been recognized by numerous awards from the Leukemia and Lymphoma Society\, the V Foundation for Cancer Research\, and the California Institute for Regenerative Medicine\, among others. He was named a Distinguished International Young Investigator in Stem Cell Research and is the 2024 recipient of the prestigious Janet Rowley Award from the International Society of Experimental Hematology.  \nTalk abstract \nHematopoietic stem cells (HSCs) persist throughout life to regenerate blood cells lost to physiological turnover\, injury and disease. But how stem cells preserve their immense regenerative potential while simultaneously sustaining their remarkable longevity remains a mystery. The regulation of protein homeostasis (proteostasis) has emerged as being fundamentally and preferentially important for HSCs. Proteostasis is maintained by an integrated network of physiological mechanisms and stress response pathways that coordinate protein synthesis\, folding\, trafficking and degradation to regulate the content and quality of the proteome. Many of these highly-conserved pathways have long been thought of as housekeeping functions\, performed similarly by most cells. However\, we found that HSCs exhibit unique cell-type-specific configuration of the proteostasis network that is critical for preserving their fitness\, health and longevity. Young adult HSCs exhibit unusually low protein synthesis rates to restrict the biogenesis of misfolded proteins in vivo and utilize non-canonical protein trafficking and degradation pathways to limit the accumulation of protein aggregation to preserve their long-term self-renewal potential. Challenges to proteostasis during aging cause HSCs to remodel their proteostasis network to sustain their fitness and regenerative potential. However\, adapting to these selective pressures comes at the cost of increasing the risk of premalignant and malignant disease. Overall\, unique and dynamic regulation of proteostasis is key for balancing stem cell regeneration and longevity.
URL:https://mbd.ccrm.ca/event/global-speaker-series-robert-signer-phd-uc-san-diego/
LOCATION:Donnelly Centre for Cellular and Biomolecular Research\, Red Room\, 160 College Street\, Toronto\, Ontario\, M5S 3E1\, Canada
CATEGORIES:Global Speaker Series
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20240514T120000
DTEND;TZID=America/Toronto:20240514T130000
DTSTAMP:20260405T130403
CREATED:20240105T165551Z
LAST-MODIFIED:20240402T164948Z
UID:33214-1715688000-1715691600@mbd.ccrm.ca
SUMMARY:Global Speaker Series: Mingxia Gu\, MD\, PhD - Cincinnati Children's Hospital Medical Center
DESCRIPTION:The Medicine by Design Global Speaker Series invites established and emerging international leaders in regenerative medicine to engage with our extraordinary community of researchers and clinicians. \nJoin speaker\, Mingxia Gu\, Assistant Professor of Pediatrics at Cincinnati Children’s Hospital Medical Center. \nHosted by Medicine by Design\, in partnership with the McEwen Stem Cell Institute.  \nTalk title: Unveiling the Mysteries of Vascular Development and Regeneration with Advanced Human Organoid Models \nREGISTER HERE\nAbout Mingxia Gu \n\n  \n  \n  \n  \nDr. Mingxia Gu is an Assistant Professor of Pediatrics at Cincinnati Children’s Hospital Medical Center. She received her medical training from Peking University in Beijing\, China\, and pursued a joint-training Ph.D. program at Peking University and Stanford University in Dr. Joseph Wu’s laboratory. Following her time as an AHA postdoctoral fellow in Dr. Marlene Rabinovitch’s lab at Stanford\, she joined Cincinnati Children’s Hospital Medical Center in early 2020\, holding joint appointments in the Center for Stem Cell & Organoid Medicine (CuSTOM) and Divisions of Pulmonary Biology\, Molecular Cardiovascular Biology\, and Developmental Biology. Dr. Gu has published at top-tier journals\, such as Cell Stem Cell\, Science Translational Medicine\, and Circulation Research\, and her lab is well-funded by NIH\, the Single Ventricle Research Foundation\, and the American Heart Association. The Gu lab focuses on dissecting signaling mechanisms guiding tissue-specific endothelial cell fate commitment and developing innovative therapeutic strategies for regenerating vascular beds in congenital heart and lung defects. \nTalk abstract \nTo investigate the co-development of vasculature\, mesenchyme\, and epithelium crucial for organogenesis and the acquisition of organ-specific characteristics\, we constructed a human pluripotent stem cell-derived organoid system comprising lung or intestinal epithelium surrounded by organotypic mesenchyme and vasculature. We demonstrated the pivotal role of co-differentiating mesoderm and endoderm via precise BMP regulation in generating multilineage organoids and gut tube patterning. Single-cell RNA-seq analysis revealed organ specificity in endothelium and mesenchyme\, and uncovered key ligands driving endothelial specification in the lung (e.g.\, WNT2B and Semaphorins) or intestine (e.g.\, GDF15). Upon transplantation under the kidney capsule in mice\, these organoids further matured and developed perfusable human-specific sub-epithelial capillaries. Additionally\, our model recapitulated the abnormal endothelial-epithelial crosstalk in patients with FOXF1 deletion or mutations. Multilineage organoids provide a unique platform to study developmental cues guiding endothelial and mesenchymal cell fate determination\, and investigate intricate cell-cell communications in human organogenesis and disease. \nThis event will be held in-person only at the Terrence Donnelly Centre for Cellular & Biomolecular Research\, Red Room.
URL:https://mbd.ccrm.ca/event/global-speaker-series-mingxia-gu-md-phd-cincinnati-childrens-hospital-medical-center/
LOCATION:Donnelly Centre for Cellular and Biomolecular Research\, Red Room\, 160 College Street\, Toronto\, Ontario\, M5S 3E1\, Canada
CATEGORIES:Global Speaker Series
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20240429T120000
DTEND;TZID=America/Toronto:20240429T130000
DTSTAMP:20260405T130403
CREATED:20240116T203138Z
LAST-MODIFIED:20240402T164803Z
UID:33380-1714392000-1714395600@mbd.ccrm.ca
SUMMARY:Global Speaker Series: Erika Moore\, PhD - University of Maryland\, College Park
DESCRIPTION:The Medicine by Design Global Speaker Series invites established and emerging international leaders in regenerative medicine to engage with our extraordinary community of researchers and clinicians. \nJoin speaker\, Erika Moore\, Assistant Professor\, Fischell Department of Bioengineering\, A. James Clark School of Engineering\, University of Maryland\, College Park. \nHosted by Medicine by Design\, in partnership with the McEwen Stem Cell Institute.  \nTalk title: Bridging the Gap: In vitro Preclinical Models to Investigate the Role of Macrophages in Tissue Regeneration \nRegister here\nAbout Erika Moore \n\nDr. Erika Moore is an Assistant Professor in the Fischell Department of Bioengineering at the University of Maryland\, College Park. She defended her Ph.D. in Biomedical Engineering from Duke University in May 2018. She earned her bachelor’s degree in Biomedical Engineering from the Johns Hopkins University in 2013. Her work focuses on understanding the role of macrophage immune cells in tissue repair and regeneration through the design of in vitro preclinical models\, spanning age-associated macrophage function\, macrophage-vasculitis mediation in lupus\, and macrophage integrin ligand interactions within the extracellular matrix. The mission of the Moore lab is to engineer biomaterial models that leverage the regenerative potential of the immune system across health inequities. To execute on this mission\, Dr. Moore develops compassionate innovators equipped to transform biomedical research. Recently acknowledged as Forbes 30 Under 30 in the Healthcare category\, Dr. Moore’s notable awards include the N.I.H. R35 Maximizing Investigators Research Award\, the Lupus Research Alliance Career Development Award\, the BMES Rita Schaffer Award\, the 3M Non-Tenured Faculty Award and NSF CAREER Award. \nThis event will be held in-person only at the Terrence Donnelly Centre for Cellular & Biomolecular Research\, Red Room.
URL:https://mbd.ccrm.ca/event/global-speaker-series-erika-moore-phd-university-of-maryland-college-park/
LOCATION:Donnelly Centre for Cellular and Biomolecular Research\, Red Room\, 160 College Street\, Toronto\, Ontario\, M5S 3E1\, Canada
CATEGORIES:Global Speaker Series
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20240312T120000
DTEND;TZID=America/Toronto:20240312T130000
DTSTAMP:20260405T130403
CREATED:20230921T175724Z
LAST-MODIFIED:20240213T154021Z
UID:21198-1710244800-1710248400@mbd.ccrm.ca
SUMMARY:Global Speaker Series: Shruti Naik\, PhD - New York University Grossman School of Medicine
DESCRIPTION:The Medicine by Design Global Speaker Series invites established and emerging international leaders in regenerative medicine to engage with our extraordinary community of researchers and clinicians. \nJoin speaker\, Shruti Naik\, Associate Professor in Pathology\, Medicine and Dermatology and Associate Director of the Colton Center for Autoimmunity at NYU Grossman School of Medicine. \nTalk title: Immune-mediated mechanisms of tissue adaptation and maladaptation. \nREGISTER HERE\nAbout Shruti Naik \n\n  \n  \n  \n  \nDr. Shruti Naik\, Ph.D.\, holds the position of Associate Professor in Pathology\, Medicine and Dermatology and also serves as the Associate Director of the Colton Center for Autoimmunity at NYU Grossman School of Medicine. \nDr. Naik is an international leader in immunology and regenerative medicine. Her research examines how Psoriasis and Inflammatory Bowel Disease\, the most common chronic inflammatory diseases that collectively affect ~5% of the Western population\, profoundly impair organ function. By leveraging cutting-edge technologies to study mechanisms of how immune cells comminate with tissues in health and disease\, Naik seeks to develop curative therapies that halt inflammatory damage and rejuvenate organs at the cellular and molecular level. \nDr. Naik earned her B.S. in Cell and Molecular Biology from the University of Maryland College Park and subsequently obtained her Ph.D. through the University of Pennsylvania-NIH graduate partnership program under the mentorship of Drs. Yasmine Belkaid and Julie Segre. She further honed her expertise as s Damon Runyon Postdoctoral Fellow at the Rockefeller University in New York City. \nIn addition to her outstanding research contributions\, Dr. Naik is a strong advocate for increasing diversity in science. She is also committed to mentoring the next generation of scientists and physicians. Her involvement extends to serving on Scientific Advisory Board of the Keystone Symposium and her role as an Executive Producer of the film Six Degrees from Science. Dr. Naik has received numerous accolades for her groundbreaking research and advocacy including the Regeneron Award for Creative Innovation\, the L’Oréal For Women in Science Award\, the Damon Runyon Dale F. Frey Award for Breakthrough Scientist\, the Blavatnik Award for Young Scientists\, the International Takeda International Innovators in Science Award\, Pew-Stewart Scholar\, NIH Directors Innovator Award DP2\, Packard Fellow\, Burrows Welcome PATH award\, and is a NYSCF Robertson Stem Cell Investigator. \nTalk abstract \nThe epithelial tissues that line our body routinely experience inflammation inducing pathogenic and noxious agents. The mechanisms and consequences of how epithelial tissues\, and in particular their long-lived stem cells\, sense\, respond to\, and remember such encounters are only now beginning to unfold. I discuss the crosstalk between immune cells\, epithelial stem cells\, and c microbes and its importance for epithelial health and repair. Understanding these dynamic interactions may provide unique means of boosting epithelial barrier function and healing by modulating immune and microbial signals perceived by stem cells \nHosted by Medicine by Design\, in partnership with the McEwen Stem Cell Institute.  \n This event will be held in-person only at the Terrence Donnelly Centre for Cellular & Biomolecular Research\, Red Room. \n 
URL:https://mbd.ccrm.ca/event/global-speaker-series-shruti-naik-phd-new-york-university-school-of-medicine/
LOCATION:Donnelly Centre for Cellular and Biomolecular Research\, Red Room\, 160 College Street\, Toronto\, Ontario\, M5S 3E1\, Canada
CATEGORIES:Global Speaker Series
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20240206T120000
DTEND;TZID=America/Toronto:20240206T130000
DTSTAMP:20260405T130403
CREATED:20230921T175131Z
LAST-MODIFIED:20240131T150148Z
UID:21193-1707220800-1707224400@mbd.ccrm.ca
SUMMARY:Global Speaker Series: Bernard Thébaud\, MD\, PhD – Ottawa Hospital Research Institute
DESCRIPTION:The Medicine by Design Global Speaker Series invites established and emerging international leaders in regenerative medicine to engage with our extraordinary community of researchers and clinicians. \nJoin speaker Bernard Thébaud\, Senior Scientist\, Regenerative Medicine Program\, Ottawa Hospital Research Institute\, Neonatologist\, Department of Pediatrics\, The Ottawa Hospital and the Children’s Hospital of Eastern Ontario\, Professor\, Department of Pediatrics and Partnership Research Chair\, Regenerative Medicine\, University of Ottawa. \nHosted by Medicine by Design\, in partnership with the McEwen Stem Cell Institute.  \nTalk title: Helping Underdeveloped Lungs with Cells – The HULC trials from Petri dish to Patient  \nREGISTER HERE\nAbout Bernard Thébaud \n\n  \n  \n  \n  \nDr. Bernard Thébaud is a clinician-scientist with a focus on the clinical translation of stem cell-based therapies for lung diseases. He is a senior scientist with the Ottawa Hospital Research Institute and a neonatologist with the Children’s Hospital of Eastern Ontario\, providing care to critically ill newborns. He is also a Professor of Pediatrics at the University of Ottawa.  Dr. Thébaud obtained his MD at the University Louis Pasteur in Strasbourg in France and trained in Pediatrics and Neonatology at the University Paris V\, where he obtained his MSc and PhD before completing a 2-year postdoctoral fellowship at the University of Alberta.  \nDr. Thébaud studies the mechanisms of lung development\, injury and repair to design new treatments for incurable lung diseases. His focus is on answering clinically relevant questions for translation into real-life applications. He is now translating innovative cell and gene therapies from the lab into patients to improve outcomes.  Dr. Thébaud has participated on numerous peer reviews committees and scientific advisory boards at the international\, national and provincial level\, including CIHR and NIH. Dr. Thébaud holds the University of Ottawa Partnership Research Chair in Regenerative Medicine. His research is funded by the Canadian Institutes of Health Research\, the Heart and Stroke Foundation of Canada\, and the Stem Cell Network.  \nTalk abstract \nPreterm birth is a leading cause of infant morbidity and mortality worldwide. Bronchopulmonary dysplasia (BPD)\, the chronic lung disease that follows ventilator and O2 therapy for acute respiratory failure\, is the most common complication of prematurity and accounts for much of the long-term morbidity. BPD lacks effective therapies. Experimental data over the past 15 years have provided some evidence for the potential for cell-based therapies to prevent neonatal lung injury and have led to early phase clinical trials using mesenchymal stromal cells. This presentation will summarize the hazardous path from Petri dish to Patient and acknowledge the current stage of infancy of cell-based therapy. Much more needs to be learned about the biology of these putative repair cells in order to fully harness their therapeutic potential.  \nThis event will be held in-person only at the Terrence Donnelly Centre for Cellular & Biomolecular Research\, Red Room.
URL:https://mbd.ccrm.ca/event/global-speaker-series-bernard-thebaud-md-phd-ottawa-hospital-research-institute/
LOCATION:Donnelly Centre for Cellular and Biomolecular Research\, Red Room\, 160 College Street\, Toronto\, Ontario\, M5S 3E1\, Canada
CATEGORIES:Global Speaker Series
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20240123T120000
DTEND;TZID=America/Toronto:20240123T130000
DTSTAMP:20260405T130403
CREATED:20230921T175506Z
LAST-MODIFIED:20240111T143704Z
UID:21196-1706011200-1706014800@mbd.ccrm.ca
SUMMARY:Global Speaker Series: Ana Andreazza\, PhD - University of Toronto
DESCRIPTION:The Medicine by Design Global Speaker Series invites established and emerging international leaders in regenerative medicine to engage with our extraordinary community of researchers and clinicians. \nJoin speaker Ana Andreazza\, Professor in the Departments of Pharmacology & Toxicology and Psychiatry at the University of Toronto\, Tier II Canada Research Chair in Molecular Pharmacology of Mood Disorders\, and Thomas C. Zachos Chair in Mitochondrial Research. \nHosted by Medicine by Design\, in partnership with the McEwen Stem Cell Institute.  \nTalk title: Brain\, mitochondria & metabolism: A transdiagnostic dimension \nREGISTER HERE\n  \nAbout Ana Andreazza \n\n  \n  \n  \n  \nAs a Professor at the University of Toronto in Pharmacology & Toxicology and Psychiatry\, I hold the Tier II Canada Research Chair in Molecular Pharmacology of Mood Disorders and the Thomas C. Zachos Chair in Mitochondrial Research. I am also the Founder and Scientific Director of the Mitochondrial Innovation Initiative\, a Senior Fellow of Massey College\, and a Member of the Royal Society of Canada College of New Scholars. \nMy research primarily explores the role of mitochondrial function in health and disease\, focusing on neurological and psychiatric disorders\, organ transplant and regeneration\, and novel therapeutics for mitochondrial health improvement. A key area is the study of mitochondrial function in mood disorders like bipolar disorder (BD)\, where I’ve identified dysregulation in mitochondrial genes and are now using 3D brain organoids to investigate neurotransmission impacts. This could lead to personalized treatments for mood and mitochondrial disorders. In organ transplantation\, my work centers on preserving donor organs\, especially lungs\, and improving transplantation outcomes. This involves studying cell metabolism and mitochondrial health\, contributing to better donor-recipient matches and enhancing patient care. I also pioneer in mitochondrial transplantation and therapy\, exploring the stability\, safety\, and efficacy of mitochondria transplant for regenerative medicine and chronic diseases. \nFinally\, my approach integrates cross-disciplinary collaboration\, intertwining mitochondrial function with various health aspects. Leading the Mitochondrial Innovation Initiative\, I drive advances in mitochondrial biology and its health implications\, promoting knowledge exchange and groundbreaking discoveries for patient and societal benefits. \nThis event will be held in-person only at the Terrence Donnelly Centre for Cellular & Biomolecular Research\, Red Room.
URL:https://mbd.ccrm.ca/event/global-speaker-series-ana-andreazza-phd/
LOCATION:Donnelly Centre for Cellular and Biomolecular Research\, Red Room\, 160 College Street\, Toronto\, Ontario\, M5S 3E1\, Canada
CATEGORIES:Global Speaker Series
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20231114T120000
DTEND;TZID=America/Toronto:20231114T130000
DTSTAMP:20260405T130404
CREATED:20220714T013512Z
LAST-MODIFIED:20231005T173639Z
UID:17697-1699963200-1699966800@mbd.ccrm.ca
SUMMARY:Global Speaker Series: Claudia Fischbach-Teschl\, PhD – Cornell University
DESCRIPTION:The Medicine by Design Global Speaker Series invites established and emerging international leaders in regenerative medicine to engage with our extraordinary community of researchers and clinicians. \nJoin speaker Claudia Fischbach-Teschl\,  Professor\, Biomedical Engineering\, Cornell University\, Director of Cornell’s Physical Sciences Oncology Center (PSOC) on the Physics of Cancer Metabolism\, and Associate Director of Cornell Nanoscale Science and Engineering Facility (CNF). Read more about Professor Fischbach-Teschl. \nHosted by Medicine by Design\, in partnership with the McEwen Stem Cell Institute. \nTalk title: Physical sciences approaches to analyze tumor-associated ECM dynamics. \nRegister here\nAbout Claudia Fischbach-Teschl \n\n  \nClaudia Fischbach-Teschl is the Stanley Bryer 1946 Professor of Biomedical Engineering at Cornell University and Associate Director of Cornell Nanoscale Science and Engineering Facility (CNF). She received her Ph.D. in Pharmaceutical Technology from the University of Regensburg\, Germany and conducted her postdoctoral work at Harvard University in the Division of Engineering and Applied Sciences. Her lab utilizes engineering tools and strategies to gain a better understanding of how tumor-microenvironment interactions regulate cancer development\, progression\, and therapy resistance with a focus on cell-ECM interactions. She is a fellow of the American Institute for Medical and Biological Engineering (AIMBE)\, the Biomedical Engineering Society\, and the Alexander von Humboldt Foundation in Germany. She is the recipient of the Momentum Mid-Career Award by the Cellular and Molecular Bioengineering Special Interest Group of the Biomedical Engineering Society (BMES) and the inaugural awardee of a Rosalind Franklin Award by the Max Planck Centre for Physics in Medicine in Germany. She is a Senior Editor of Cancer Research\, and serves on the Editorial Board of the ACS journal Biomaterials Science and Engineering and Tissue Engineering. She is an advocate for interdisciplinary cancer research and has written Op-Ed articles on this topic including in Scientific American.  \nTalk abstract \nMicroenvironmental conditions contribute to the pathogenesis of cancer and include altered cellular composition\, extracellular matrix (ECM) deposition\, and mechanical cues. However\, our understanding of the specific mechanisms by which these microenvironmental perturbations impact the development\, progression\, and therapy response of cancer is relatively limited. More intricate models are needed to better understand the complex biochemical and biophysical interactions that drive tumor initiation\, growth\, metastasis\, metabolic adaptation\, and immune evasion. The fields of biomaterials and tissue engineering provide increasingly sophisticated tools and strategies to recapitulate and monitor relevant properties of tumor-microenvironment interactions. These approaches not only bear tremendous potential to advance our current understanding of cancer\, but are also increasingly explored for more clinically relevant drug testing. Indeed\, combining patient-specific cells with engineered culture systems promises to enhance the predictive power of precision medicine pipelines. This talk will highlight specific examples of how the microenvironment regulates the highly dynamic nature of cancer and will outline opportunities and challenges of the field of tumor engineering.  \n This event will be held in-person only at the Terrence Donnelly Centre for Cellular & Biomolecular Research\, Red Room.
URL:https://mbd.ccrm.ca/event/global-speaker-series-nov-2023/
LOCATION:Donnelly Centre for Cellular and Biomolecular Research\, Red Room\, 160 College Street\, Toronto\, Ontario\, M5S 3E1\, Canada
CATEGORIES:Global Speaker Series
ORGANIZER;CN="Medicine by Design":MAILTO:info.mbd@utoronto.ca
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20231017T120000
DTEND;TZID=America/Toronto:20231017T130000
DTSTAMP:20260405T130404
CREATED:20220714T141111Z
LAST-MODIFIED:20230921T134623Z
UID:17712-1697544000-1697547600@mbd.ccrm.ca
SUMMARY:Global Speaker Series: Qizhi Tang\, PhD – University of California\, San Francisco
DESCRIPTION:The Medicine by Design Global Speaker Series invites established and emerging international leaders in regenerative medicine to engage with our extraordinary community of researchers and clinicians. \nMedicine by Design\, in partnership with the McEwen Stem Cell Institute\, is pleased to welcome Qizhi Tang\, PhD. Professor Tang is a professor of surgery in the Division of Transplant Surgery and director\, Transplantation Research Laboratory from the University of California\, San Francisco. Learn more about the Tang lab. \nRegister for in-person\nThis event will be held in person at the Terrence Donnelly Centre for Cellular & Biomolecular Research\, Red Room. \nTalk title: Helping pancreatic beta cells survive after transplant \n\nAbout Qizhi Tang \n\n  \nDr. Qizhi Tang is a professor of immunology in the UCSF Diabetes Center\, the Department of Surgery\, the Gladstone Institute of Genomic Immunology\, and the Institute of Regenerative Medicine at the University of California\, San Francisco (UCSF). She studied medicine at Peking Union Medical College. After a 6-month research internship during year 5 of the 8-year MD program\, she left the program to pursue graduate study in the US. She studied viral immunology at the University of Illinois in Chicago for her PhD. For her postdoctoral fellowship\, she studied cellular and molecular mechanisms of immune tolerance under the tutelage of Jeffrey bluestone\, first at the University Chicago and then at UCSF. She served as the director of the UCSF Transplantation Research Lab for 14 years from 2007 to 2021. She is currently the director of the Northern California JDRF Center of Excellence. \nOne major research focus in the Tang Lab has been on investigating regulatory T cell control of autoimmune diabetes and transplant rejection. In the past 10 years\, she has led translational efforts to design and implement 10 Treg-based clinical trials in autoimmune diseases and organ transplantation. Currently\, pre-clinical research in her lab focuses on developing cellular engineering strategies to enhance human Treg potency and stability. Another area of research in the Tang lab is to optimize beta cell replacement therapy for type 1 diabetes by improving islet survival in ischemia and designing strategies to avoid immune rejection without systemic immunosuppression. \nTalk abstract \nPancreatic beta cell replacement therapy has the potential to cure type 1 diabetes by replacing lost beta cells.  The therapy is limited by the poor survival of the transplanted cells and the need for life-long immunosuppression.  The presentation will describe ongoing efforts to tackle these challenges using cell engineering strategies.
URL:https://mbd.ccrm.ca/event/global-speaker-series-oct-2023/
LOCATION:Donnelly Centre for Cellular and Biomolecular Research\, Red Room\, 160 College Street\, Toronto\, Ontario\, M5S 3E1\, Canada
CATEGORIES:Global Speaker Series
ORGANIZER;CN="Medicine by Design":MAILTO:info.mbd@utoronto.ca
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20230926T120000
DTEND;TZID=America/Toronto:20230926T130000
DTSTAMP:20260405T130404
CREATED:20220714T141149Z
LAST-MODIFIED:20230912T134906Z
UID:17711-1695729600-1695733200@mbd.ccrm.ca
SUMMARY:Global Speaker Series - Miriam Merad\, MD\, PhD\, Icahn School of Medicine\, Mount Sinai
DESCRIPTION:The Medicine by Design Global Speaker Series invites established and emerging international leaders in regenerative medicine to engage with our extraordinary community of researchers and clinicians. \nMedicine by Design\, in partnership with the McEwen Stem Cell Institute\, is pleased to welcome Miriam Merad\, MD\, PhD. Miriam Merad is the Director of the Precision Immunology Institute at Mount Sinai School of Medicine in New York and the Director of the Mount Sinai Human Immune Monitoring Center (HIMC). \nTalk title: Targeting myeloid cells in cancer and inflammatory diseases \nThis is a virtual event.\n\nVirtual event links will be sent after registration.\n\nRegister here\n\nAbout Miriam Merad \n\n  \nDr. Merad is an internationally acclaimed physician-scientist and a leader in the fields of dendritic cell and macrophage biology with a focus on their contribution to human diseases. Dr. Merad identified the tissue-resident macrophage lineage and revealed its distinct role in organ physiology and pathophysiology. She established the contribution of this macrophage lineage to cancer progression and inflammatory diseases and is now working on developing novel macrophage-targeted therapies for these conditions. In addition to her work on macrophages\, Dr. Merad is known for her work on dendritic cells\, which control adaptive immunity. She identified a new subset of dendritic cells\, now considered a key antiviral and antitumor immunity target. \nDr. Merad leads the Precision Immunology Institute at the Icahn School of Medicine (PrIISM) to bring immunology discoveries to the clinic. PrIISM integrates immunological research programs with synergistic expertise in biology\, medicine\, technology\, physics\, mathematics\, and computational biology to enhance our understanding of human immunology. She also founded the Human Immune Monitoring Center at Mount Sinai\, one of the world’s most sophisticated research centers\, which uses cutting-edge single-cell technology to understand the contribution of immune cells to major human diseases or treatment responses. \nDr. Merad has authored more than 200 primary papers and reviews in high-profile journals. Her work has been cited several thousand times. She receives generous funding from the National Institutes of Health (NIH) for her research on innate immunity and its contribution to human disease and belongs to several NIH consortia. She is an elected member of the American Society of Clinical Investigation and the recipient of the William B. Coley Award for Distinguished Research in Basic and Tumor Immunology. She is the President of the International Union of Immunological Societies (IUIS). In 2020\, she was elected to the National Academy of Sciences in recognition of her contributions to the field of immunology. \n  \n 
URL:https://mbd.ccrm.ca/event/global-speaker-series-sept-2023/
LOCATION:Ontario
CATEGORIES:Global Speaker Series
ORGANIZER;CN="Medicine by Design":MAILTO:info.mbd@utoronto.ca
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20230606T120000
DTEND;TZID=America/Toronto:20230606T130000
DTSTAMP:20260405T130404
CREATED:20230411T143207Z
LAST-MODIFIED:20230508T200241Z
UID:19810-1686052800-1686056400@mbd.ccrm.ca
SUMMARY:Global Speaker Series: Omolola Eniola-Adefeso\, PhD - University of Michigan
DESCRIPTION:The Medicine by Design Global Speaker Series invites established and emerging international leaders in regenerative medicine to engage with our extraordinary community of researchers and clinicians. \nMedicine by Design\, in partnership with the McEwen Stem Cell Institute\, is pleased to welcome Omolola Eniola-Adefeso\, PhD\, from the University of Michigan. \nTalk title: Leveraging the Natural Cellular and Biomolecular Interactions in Blood for the Design of Targeted\, Anti-Inflammatory Particle Therapeutics. \nRegister for in-person\nAbout Omolola Eniola-Adefeso \n \nDr. Omolola Eniola-Adefeso is the University Diversity and Social Transformation Professor of Chemical Engineering and Biomedical Engineering at the University of Michigan-Ann Arbor. She received a doctoral degree (2004) in Chemical and Biomolecular Engineering at the University of Pennsylvania. She was a postdoctoral associate in the Pediatrics/Leukocyte Biology at Baylor College of Medicine. Dr. Eniola-Adefeso joined the faculty of Chemical Engineering at the University of Michigan in 2006\, where she runs the Cell Adhesion and Drug Delivery Laboratory. Since she arrived at Michigan\, Dr. Eniola-Adefeso has received several honors and awards\, including the NSF CAREER Award\, American Heart Association Innovator Award\, and most recently\, the BMES MIDCAREER Award. She is a fellow of the American Institute for Medical and Biological Engineering (AIMBE) and the Biomedical Engineering Society and serves as Deputy Editor for Science Advances. Her research is currently funded by multiple grants from the NIH NHLBI\, American Heart Association\, and the National Science Foundation. \nTalk abstract \nVascular-targeted particle therapeutics offer the possibility of increased drug effectiveness while minimizing side effects often associated with systemic drug administration. Factors that influence the likelihood of targeted particle therapeutics to reach the vascular wall are the ability to identify: 1) a disease-specific target\, 2) the appropriate drug carrier type and geometry for efficient interaction with the vascular wall\, and 3) a drug-carrier combination that allows for the desired release of the targeted therapeutics. Our work focuses on probing the role of particle geometry\, material chemistry\, and blood rheology/dynamics on the ability of vascular-targeted drug carriers to interact with the blood vessel wall – an important consideration that will control the effectiveness of drug targeting regardless of the targeted disease or delivered therapeutically. This presentation will highlight the carrier-blood cell interactions that affect drug carrier binding to the vascular wall and alter critical neutrophil functions in disease. The talk will present the material design parameters for optimal drug carriers’ design for active and passive use in treating acute lung injury and other inflammatory diseases. \nThis event will be held in-person only at the Terrence Donnelly Centre for Cellular & Biomolecular Research\, Red Room.
URL:https://mbd.ccrm.ca/event/global-speaker-series-lola-eniola-adefeso-phd-university-of-michigan/
LOCATION:Donnelly Centre for Cellular and Biomolecular Research\, Red Room\, 160 College Street\, Toronto\, Ontario\, M5S 3E1\, Canada
CATEGORIES:Global Speaker Series
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20230420T120000
DTEND;TZID=America/Toronto:20230420T130000
DTSTAMP:20260405T130404
CREATED:20230104T152027Z
LAST-MODIFIED:20230328T132833Z
UID:19171-1681992000-1681995600@mbd.ccrm.ca
SUMMARY:Global Speaker Series: Jean-Laurent Casanova\, MD\, PhD – Rockefeller University
DESCRIPTION:The Medicine by Design Global Speaker Series invites established and emerging international leaders in regenerative medicine to engage with our extraordinary community of researchers and clinicians. \nMedicine by Design\, in partnership with the McEwen Stem Cell Institute\, is pleased to welcome Jean-Laurent Casanova\, MD\, PhD\, from Rockefeller University. \nTalk title: The human genetic and immunological determinants of life-threatening COVID-19 \nRegister for virtual\nRegister for in-person\nAbout Jean-Laurent Casanova\n \n \nJean-Laurent Casanova received his MD in 1987 and his PhD in 1992\, after training at the Pasteur Institute in Paris and the Ludwig Institute for Cancer Research in Lausanne. He was appointed professor at Necker in 1999 and with Laurent Abel\, co-founded the Laboratory of Human Genetics of Infectious Diseases. He was appointed professor at Rockefeller University in 2008 and named HHMI investigator in 2014. He continues to partner with Dr. Abel\, maintaining their lab in Paris and NY. \nCasanova studies the human genetic and immunological determinants of life-threatening infectious diseases. He searches for rare and common single-gene mutations that selectively compromise immunity of otherwise healthy individuals who are vulnerable to specific infectious diseases. He then searches for other causes disrupting the same mechanisms of host defense\, and thus characterizes the causal mechanisms of life-threatening infectious diseases. \nTalk abstract\nAutosomal inborn errors of type I IFN immunity and autoantibodies against these cytokines underlie at least 10% of critical COVID-19 pneumonia cases. We report very rare\, biochemically deleterious X-linked TLR7 variants in 16 unrelated male individuals aged 7 to 71 years (mean: 36.7 years) from a cohort of 1\,202 male patients aged 0.5 to 99 years (mean: 52.9 years) with unexplained critical COVID-19 pneumonia. None of the 331 asymptomatically or mildly infected male individuals aged 1.3 to 102 years (mean: 38.7 years) tested carry such TLR7 variants (p = 3.5 × 10-5). The phenotypes of five hemizygous relatives of index cases infected with SARS-CoV-2 include asymptomatic or mild infection (n=2\, 5 and 38 years)\, or moderate (n=1\, 5 years)\, severe (n=1\, 27 years)\, or critical (n=1\, 29 years) pneumonia. Two boys (aged 7 and 12 years) from a cohort of 262 male patients with severe COVID-19 pneumonia (mean: 51.0 years) are hemizygous for a deleterious TLR7 variant. The cumulative allele frequency for deleterious TLR7 variants in the male general population is < 6.5×10-4 We also show that blood B cell lines and myeloid cell subsets from the patients do not respond to TLR7 stimulation\, a phenotype rescued by wild-type TLR7 The patients’ blood plasmacytoid dendritic cells (pDCs) produce low levels of type I IFNs in response to SARS-CoV-2. Overall\, X-linked recessive TLR7 deficiency is a highly penetrant genetic etiology of critical COVID-19 pneumonia\, in about 1.8% of male patients below the age of 60 years. Human TLR7 and pDCs are essential for protective type I IFN immunity against SARS-CoV-2 in the respiratory tract. Furthermore\, circulating autoantibodies (auto-Abs) neutralizing high concentrations (10 ng/mL\, in plasma diluted 1 to 10) of IFN-α and/or -ω are found in about 10% of patients with critical COVID-19 pneumonia\, but not in subjects with asymptomatic infections. We detect auto-Abs neutralizing 100-fold lower\, more physiological\, concentrations of IFN-α and/or -ω (100 pg/mL\, in 1/10 dilutions of plasma) in 13.6% of 3\,595 patients with critical COVID-19\, including 21% of 374 patients > 80 years\, and 6.5% of 522 patients with severe COVID-19. These antibodies are also detected in 18% of the 1\,124 deceased patients (aged 20 days-99 years; mean: 70 years). Moreover\, another 1.3% of patients with critical COVID-19 and 0.9% of the deceased patients have auto-Abs neutralizing high concentrations of IFN-β. We also show\, in a sample of 34\,159 uninfected subjects from the general population\, that auto-Abs neutralizing high concentrations of IFN-α and/or -ω are present in 0.18% of individuals between 18 and 69 years\, 1.1% between 70 and 79 years\, and 3.4% >80 years. Moreover\, the proportion of subjects carrying auto-Abs neutralizing lower concentrations is greater in a subsample of 10\,778 uninfected individuals: 1% of individuals <70 years\, 2.3% between 70 and 80 years\, and 6.3% >80 years. By contrast\, auto-Abs neutralizing IFN-β do not become more frequent with age. Auto-Abs neutralizing type I IFNs predate SARS-CoV-2 infection and sharply increase in prevalence after the age of 70 years. They account for about 20% of both critical COVID-19 cases in the over-80s\, and total fatal COVID-19 cases.
URL:https://mbd.ccrm.ca/event/global-speaker-series-jean-laurent-casanova-phd/
LOCATION:ONRamp\, 100 College St\, Suite 150\, Toronto\, M5G 1L5\, Canada
CATEGORIES:Global Speaker Series
ORGANIZER;CN="Medicine by Design":MAILTO:info.mbd@utoronto.ca
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20230314T130000
DTEND;TZID=America/Toronto:20230314T140000
DTSTAMP:20260405T130404
CREATED:20230104T143408Z
LAST-MODIFIED:20230222T191147Z
UID:19172-1678798800-1678802400@mbd.ccrm.ca
SUMMARY:Global Speaker Series: Domitilla Del Vecchio\, PhD – Massachusetts Institute of Technology
DESCRIPTION:The Medicine by Design Global Speaker Series invites established and emerging international leaders in regenerative medicine to engage with our extraordinary community of researchers and clinicians. \nMedicine by Design\, in partnership with the McEwen Stem Cell Institute\, is pleased to welcome Domitilla Del Vecchio\, PhD\, from the Massachusetts Institute of Technology. \nTalk title: Synthetic genetic circuits to uncover and enforce the OCT4 trajectories of successful reprogramming of human fibroblasts. \nRegister for virtual\nRegister for in-person\nAbout the Del Vecchio lab\n \n \nDomitilla Del Vecchio received the PhD degree in Control and Dynamical Systems from the California Institute of Technology\, Pasadena\, and the Laurea degree in Electrical Engineering (Automation) from the University of Rome at Tor Vergata in 2005 and 1999\, respectively. From 2006 to 2010\, she was an Assistant Professor in the Department of Electrical Engineering and Computer Science and in the Center for Computational Medicine and Bioinformatics at the University of Michigan\, Ann Arbor. In 2010\, she joined the Department of Mechanical Engineering at the Massachusetts Institute of Technology (MIT)\, where she is currently Professor and member of the Synthetic Biology Center. She is a Fellow of the International Federation of Automatic Control (2022)\, an IEEE Fellow (2021)\, and a recipient of the Newton Award for Transformative Ideas during the COVID-19 Pandemic (2020)\, the 2016 Bose Research Award (MIT)\, the Donald P. Eckman Award from the American Automatic Control Council (2010)\, the NSF Career Award (2007)\, the American Control Conference Best Student Paper Award (2004)\, and the Bank of Italy Fellowship (2000). Her research focuses on developing techniques to make synthetic genetic circuits robust to context and on applying these to biosensing and cell fate control for regenerative medicine applications. \n  \nTalk abstract\nReprogramming human fibroblasts to induced pluripotent stem cells (iPSCs) is inefficient\, with heterogeneity among transcription factor (TF) trajectories driving divergent cell states. Nevertheless\, the impact of TF dynamics on reprogramming efficiency remains uncharted. In this work\, we identify the successful reprogramming trajectories of the core pluripotency TF\, OCT4\, and design a genetic controller that enforces such trajectories with high precision. By combining a genetic circuit that generates a wide range of OCT4 trajectories with live cell imaging\, we track OCT4 trajectories with clonal resolution and find that a distinct constant OCT4 trajectory is required for colony formation. We then develop a genetic controller circuit that yields a tight OCT4 distribution around the identified trajectory. In terms of reprogramming efficiency\, this controller outperforms other circuits that less accurately regulate OCT4. Our approach is generalizable for identifying and enforcing TF dynamics for cell fate programming applications.
URL:https://mbd.ccrm.ca/event/global-speaker-series-domitilla-del-vecchio-phd/
LOCATION:Donnelly Centre for Cellular and Biomolecular Research\, Red Room\, 160 College Street\, Toronto\, Ontario\, M5S 3E1\, Canada
CATEGORIES:Global Speaker Series
ORGANIZER;CN="Medicine by Design":MAILTO:info.mbd@utoronto.ca
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20230223T130000
DTEND;TZID=America/Toronto:20230223T140000
DTSTAMP:20260405T130404
CREATED:20220714T012204Z
LAST-MODIFIED:20230206T185723Z
UID:17688-1677157200-1677160800@mbd.ccrm.ca
SUMMARY:Global Speaker Series: Jeff Biernaskie\, PhD – University of Calgary
DESCRIPTION:The Medicine by Design Global Speaker Series invites established and emerging international leaders in regenerative medicine to engage with our extraordinary community of researchers and clinicians. Medicine by Design\, in partnership with the McEwen Stem Cell Institute\, is pleased to welcome Jeff Biernaskie\, PhD\, from the University of Calgary. \nTalk title: Insights into the determinants of tissue regeneration versus scar formation. \nThis is a hybrid event. Register for the in-person or virtual option. Lunch will be served to in-person registrants. \nThis event is also being sponsored by the Collaborative Specialization in Developmental Biology. \nRegister now for virtual\nRegister now for in-person  \nAbout the Biernaskie lab\n \n \nDr. Biernaskie completed his BSc in Neuroscience at the University of Lethbridge. He earned a PhD in Neuroscience at Memorial University studying the effects of focused rehabilitative experience on brain plasticity following stroke. He completed postdoctoral training with Freda Miller and David Kaplan studying skin and neural stem cell biology at the Hospital for Sick Children in Toronto. In 2009\, he joined the Faculty of Veterinary Medicine at the University of Calgary\, where is he currently a Professor in Stem Cell Biology and Regenerative Medicine. He is a member of the Alberta Children’s Hospital Research Institute and the Hotchkiss Brain Institute and he holds the Calgary Firefighters Burn Treatment Society Chair in Skin Regeneration and Wound Healing. In 2019\, he was elected as a member of the Royal Society of Canada\, College of Scholars\, Artists and Scientists. \nHis research program is focused on understanding the cellular and molecular mechanisms that promote fibrotic versus regenerative healing with the goal of developing treatments to restore organ function following injury or disease. His group is also interested in how skin and brain stem/progenitor cells are regulated during homeostasis and how factors like injury\, advanced aging and the immune system impact their function. \nTalk abstract\nAdult mammals have evolved to heal deep skin wounds by forming fibrotic scar in order to most efficiently fill the defect and support reepithelialisation to prevent infection. But it is unclear as to the mechanisms that drive this propensity and whether there are ways to re-awaken pro-regenerative processes in order to better restore normal function to the healed skin. I will describe our work in captive adult reindeer which provides a powerful comparative model of scarless versus fibrotic skin wound healing. Full-thickness injuries of reindeer antler skin (velvet) exhibit near-complete regeneration\, whereas back skin forms fibrotic scar. By employing single-cell multi-omics we found that even prior to injury\, velvet demal fibroblasts exhibit a transcriptional ground state that resembles human fetal fibroblasts\, whereas back skin fibroblasts express inflammatory mediators mimicking pro-fibrotic adult human and rodent fibroblasts. As a consequence of these distinct resting states\, skin injury elicited site-specific immune responses: back skin fibroblasts amplifying myeloid infiltration and maturation\, whereas velvet fibroblasts adopted an immunosuppressive phenotype that restricted leukocyte recruitment and hastened immune resolution. Finally\, I will describe additional experiments that highlight a critical role for fibroblasts in orchestrating local immune function during wound healing and that decoupling these fibroblast-immune interactions may be a promising approach to mitigate scar.
URL:https://mbd.ccrm.ca/event/global-speaker-series-feb-2023/
LOCATION:Donnelly Centre for Cellular and Biomolecular Research\, Red Room\, 160 College Street\, Toronto\, Ontario\, M5S 3E1\, Canada
CATEGORIES:Global Speaker Series
ORGANIZER;CN="Medicine by Design":MAILTO:info.mbd@utoronto.ca
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20230117T120000
DTEND;TZID=America/Toronto:20230117T130000
DTSTAMP:20260405T130404
CREATED:20220714T013546Z
LAST-MODIFIED:20230118T213640Z
UID:17674-1673956800-1673960400@mbd.ccrm.ca
SUMMARY:Global Speaker Series: Matthias Lutolf\, PhD – École Polytechnique Fédérale de Lausanne
DESCRIPTION:The Medicine by Design Global Speaker Series invites established and emerging international leaders in regenerative medicine to engage with our extraordinary community of researchers and clinicians. \nMedicine by Design\, in partnership with the McEwen Stem Cell Institute\, is pleased to welcome Matthias Lutolf\, PhD\, from the École Polytechnique Fédérale de Lausanne to give a talk titled\, “Engineering Organoid Development.” This event will be virtual. \nRegister now\n\nAbout the Lutolf lab \nMatthias Lutolf is Professor of Bioengineering at the Swiss Federal Institute of Technology Lausanne (EPFL) and founding Director of the Roche Institute for Translational Bioengineering. His research focuses on the development of advanced bioengineering strategies to produce next-generation organoids with improved reproducibility and physiological relevance for basic research and real-world applications in drug discovery and precision medicine. For example\, he pioneered the generation of organoids in fully controllable hydrogel matrices and novel approaches to control organoid patterning and morphogenesis through microfluidics\, bioprinting\, and microfabrication. \nTalk abstract: Engineering Organoid Development\nOrganoids form through poorly understood morphogenetic processes in which initially homogeneous ensembles of stem cells spontaneously self-organize in suspension or within permissive three-dimensional extracellular matrices. Yet\, the absence of virtually any predefined patterning influences such as morphogen gradients or mechanical cues results in an extensive heterogeneity. Moreover\, the current mismatch in shape\, size and lifespan between native organs and their in vitro counterparts hinders their even wider applicability. In this talk\, Matthias Lutolf will discuss some of his ongoing efforts in developing next-generation organoids that are assembled by guiding cell-intrinsic self-patterning through engineered stem cell microenvironments. \nLearn more
URL:https://mbd.ccrm.ca/event/global-speaker-series-jan-2023/
LOCATION:Ontario
CATEGORIES:Global Speaker Series
ORGANIZER;CN="Medicine by Design":MAILTO:info.mbd@utoronto.ca
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20221110T120000
DTEND;TZID=America/Toronto:20221110T130000
DTSTAMP:20260405T130404
CREATED:20220627T132515Z
LAST-MODIFIED:20221026T204249Z
UID:17497-1668081600-1668085200@mbd.ccrm.ca
SUMMARY:Global Speaker Series: Martin Fussenegger\, PhD – ETH Zurich
DESCRIPTION:The Medicine by Design Global Speaker Series invites established and emerging international leaders in regenerative medicine to engage with our extraordinary community of researchers and clinicians. Medicine by Design\, in partnership with the McEwen Stem Cell Institute\, is pleased to welcome Martin Fussenegger\, PhD\, Professor\, Department of Biosystems Science and Engineering\, ETH Zurich. The title of this talk will be\, “Toward A World of ElectroGenetics” \nIn Person – Register Here\nVirtual – Register Here\nHybrid event\, with in-person and virtual options\n\nIn-person will be held at the Terrence Donnelly Centre for Cellular & Biomolecular Research\, Red Room.\nVirtual event links will be sent after registration.\n\nMORE ABOUT MARTIN FUSSENEGGER: \n \nMartin Fussenegger is Professor of Biotechnology and Bioengineering at the Department of Biosystems Science and Engineering (D-BSSE) of the ETH Zurich in Basel as well as at the University of Basel.His research focuses on mammalian cell engineering\, in particular on the assembly of synthetic gene circuits that process complex control and closed-loop expression logic as well as on the production of theranostic designer cell implants that interface with host metabolism to correct prominent metabolic disorders. \nMartin Fussenegger graduated with Werner Arber at the Biocenter of the University of Basel (1992)\, obtained his Ph.D. in Medical Microbiology (1994) at the Max Planck Institute of Biology (Tübingen\, Germany) and continued his postdoctoral studies on host-pathogen interactions at the Max Planck Institute of Infection Biology (Berlin\, 1995). He then joined the ETH Institute of Biotechnology (1996)\, where he received his habilitation in 2000\, and became Swiss National Science Foundation Professor of Molecular Biotechnology in 2002\, prior to being awarded a Chair in Biotechnology and Bioengineering at the ETH Institute for Chemical and Bioengineering in 2004. \nMartin Fussenegger received the Gaden Award\, the Merck Cell Culture Engineering Award\, the Medal of the European Society for Animal Cell Technology (ESACT)\, the Gutenberg Chair Excellence Award\, the James E. Bailey Award and two consecutive Advanced Grant Awards of the European Research Council. \n Learn more about Martin Fussenegger
URL:https://mbd.ccrm.ca/event/global-speaker-series-martin-fussenegger-phd-eth-zurich-2/
LOCATION:Donnelly Centre for Cellular and Biomolecular Research\, Red Room\, 160 College Street\, Toronto\, Ontario\, M5S 3E1\, Canada
CATEGORIES:Global Speaker Series
ORGANIZER;CN="Medicine by Design":MAILTO:info.mbd@utoronto.ca
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20221018T120000
DTEND;TZID=America/Toronto:20221018T130000
DTSTAMP:20260405T130404
CREATED:20220627T132215Z
LAST-MODIFIED:20221011T130800Z
UID:17500-1666094400-1666098000@mbd.ccrm.ca
SUMMARY:Global Speaker Series: Jacob Hanna\, MD\, PhD -Weizmann Institute of Science
DESCRIPTION:The Medicine by Design Global Speaker Series invites established and emerging international leaders in regenerative medicine to engage with our extraordinary community of researchers and clinicians. Medicine by Design\, in partnership with the McEwen Stem Cell Institute\, is pleased to welcome Jacob Hanna\, MD\, PhD\, Senior Scientist and Professor\, Department of Molecular Genetics\, Weizmann Institute of Science. The title of this talk will be\, “Synthetic Ex Utero Embryogenesis: from Naive Pluripotent Stem Cells to Advanced Whole Embryos”. \nIn Person – Register Here \nVirtual – Register Here\nHybrid event\, with in-person and virtual options\n\nIn-person will be held at the Terrence Donnelly Centre for Cellular & Biomolecular Research\, Red Room.\nVirtual event links will be sent after registration.\n\nMORE ABOUT JACOB HANNA: \nBorn in Rama\, an Arab Palestinian village in the Galilee region of Israel\, Professor Jacob (Yaqub) Hanna earned his BSc in medical science\, PhD in immunology\, and MD in clinical medicine summa cum laude from the Hebrew University of Jerusalem. He conducted postdoctoral research at the Whitehead Institute for Biomedical Research at MIT. He joined the department of Molecular Genetics at the Weizmann Institute in 2011. \nProfessor Hanna is pioneering techniques in induced naïve pluripotency from adult cell and synthetic whole embryo models made solely from stem cells ex utero. Professor Hanna was the lead researcher in a study that showed how further-modified iPS cells could be used to treat sickle-cell anemia in mice\, the first proof of concept of the therapeutic application of iPS cells. \nDuring his postdoctoral work\, Professor Hanna received a prestigious Novartis Fellowship from the Helen Hay Whitney Foundation. In 2010\, he was awarded the Sir Charles Clore Prize for Outstanding Appointment in the Weizmann Institute. He received an EMBO Young Investigator Award (2012)\, a Rappaport Prize in biomedical research (2013)\, a Krill Prize by the Wolf Foundation (2013)\, and the Helen and Martin Kimmel Award for Innovative Investigation (2014). In 2014\, he was featured among “40 under 40” innovative scientists by the prestigious journal Cell and was elected as a member of EMBO in 2018. In 2021\, he ranked at the top of the list of 50 leading world thinkers by Prospect magazine. \n Learn more about Jacob (Yaqub) Hanna
URL:https://mbd.ccrm.ca/event/global-speaker-series-jacob-hanna-phd-weizmann-institute-of-science/
LOCATION:Donnelly Centre for Cellular and Biomolecular Research\, Red Room\, 160 College Street\, Toronto\, Ontario\, M5S 3E1\, Canada
CATEGORIES:Global Speaker Series
ORGANIZER;CN="Medicine by Design":MAILTO:info.mbd@utoronto.ca
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220920T120000
DTEND;TZID=America/Toronto:20220920T130000
DTSTAMP:20260405T130404
CREATED:20220627T132505Z
LAST-MODIFIED:20220815T210942Z
UID:17495-1663675200-1663678800@mbd.ccrm.ca
SUMMARY:Global Speaker Series: Gordon Fishell\, PhD – Harvard University
DESCRIPTION:The Medicine by Design Global Speaker Series invites established and emerging international leaders in regenerative medicine to engage with our extraordinary community of researchers and clinicians. Medicine by Design\, in partnership with the McEwen Stem Cell Institute\, is pleased to welcome Gordon Fishell\, PhD\, Professor of Neurobiology\, Harvard Medical School and the Stanley Center at the Broad. The title of this talk will be\, “The intimate dependence and remarkable precision of cortical interneurons.” In Person – Register Here \nVirtual – Register Here\nHybrid event\, with in-person and virtual options\n\nIn-person will be held at the Terrence Donnelly Centre for Cellular & Biomolecular Research\, Red Room.\nVirtual event links will be sent after registration.\n\nMore About gordon fishell:\nProfessor Fishell teaches in the department of Neurobiology at Harvard Medical center and is an institute member of the Broad institute. He was previously the associate director of the New York University (NYU) Neuroscience Institute\, Julius Raines Professor of Neuroscience and Physiology at NYU\, and director of the graduate program in neuroscience and physiology at the NYU School of Medicine. Professor Fishell completed his Ph.D. in neurobiology from the University of Toronto and conducted postdoctoral research at Columbia University and the Rockefeller University. His laboratory is interested in how the architecture of brain circuits are assembled\, with a special focus on the diverse populations of inhibitory interneurons that are found in both pallial and subpallial telencephalon. Professor Fishell’s laboratory has spent the past 20 years working to understand the inhibitory cells that regulate excitatory signaling in the brain. \n Learn more about Gordon Fishell
URL:https://mbd.ccrm.ca/event/global-speaker-series-gordon-fishell-phd-harvard-university/
LOCATION:Donnelly Centre for Cellular and Biomolecular Research\, Red Room\, 160 College Street\, Toronto\, Ontario\, M5S 3E1\, Canada
CATEGORIES:Global Speaker Series
ORGANIZER;CN="Medicine by Design":MAILTO:info.mbd@utoronto.ca
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220621T120000
DTEND;TZID=America/Toronto:20220621T130000
DTSTAMP:20260405T130404
CREATED:20220517T170108Z
LAST-MODIFIED:20220615T211439Z
UID:17239-1655812800-1655816400@mbd.ccrm.ca
SUMMARY:Global Speaker Series: Gilbert Bernier\, PhD - Université de Montréal
DESCRIPTION:The Medicine by Design Global Speaker Series invites established and emerging international leaders in regenerative medicine to engage with our extraordinary community of researchers and clinicians. \nMedicine by Design\, in partnership with the McEwen Stem Cell Institute\, is pleased to welcome Gilbert Bernier\, PhD\, Associate Professor in the Department of Neuroscience at Université de Montréal. \nThe title of this talk will be\, “Cone photoreceptor sheet transplantation for the treatment of macular degenerations” \nRegister now \nHybrid event\, with in-person and virtual options\n\nIn-person will be held at the Terrence Donnelly Centre for Cellular & Biomolecular Research\, Red Room.\nVirtual event links will be sent after registration.\n\n \nMore About Gilbert bernier:\nProfessor Gilbert Bernier performed is graduated studies in Molecular Biology at Montreal University where he characterized the gene mutated in the mouse neurological disorder dystonia musculorum. In 1997\, he moved to the Max-Planck Institute of Biophysical Chemistry in Germany to study developmental biology of the retina. Since 2001\, he is heading the laboratory of stem cell and developmental biology at Maisonneuve-Rosemont Hospital to exploit the potential of human pluripotent stem cells for the study and treatment of neurodegenerative diseases such as retinal degenerative diseases and Alzheimer’s disease. Professor Bernier has also contributed to the characterization of Polycomb group proteins function in brain cancer\, DNA repair\, and premature ageing. He is Professor at the Neuroscience Department of Montreal University since 2012. He is co-founder and CEO of StemAxonTM\, a Canadian corporation involved in the development of new treatments for neurodegenerative diseases. \n Learn more about Gilbert Bernier
URL:https://mbd.ccrm.ca/event/global-speaker-series-gilbert-bernier-phd-universite-de-montreal/
LOCATION:Donnelly Centre for Cellular and Biomolecular Research\, Red Room\, 160 College Street\, Toronto\, Ontario\, M5S 3E1\, Canada
CATEGORIES:Global Speaker Series
ORGANIZER;CN="Medicine by Design":MAILTO:info.mbd@utoronto.ca
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220517T120000
DTEND;TZID=America/Toronto:20220517T130000
DTSTAMP:20260405T130404
CREATED:20220412T163857Z
LAST-MODIFIED:20220516T134308Z
UID:16939-1652788800-1652792400@mbd.ccrm.ca
SUMMARY:Global Speaker Series: Klavs Jensen\, PhD - Massachusetts Institute of Technology
DESCRIPTION:The Medicine by Design Global Speaker Series invites established and emerging international leaders in regenerative medicine to engage with our extraordinary community of researchers and clinicians. \nMedicine by Design\, in partnership with the McEwen Stem Cell Institute\, is pleased to welcome Klavs Jensen\, PhD\, Warren K. Lewis Professor\, Chemical Engineering\, and Professor\, Materials Science and Engineering\, Massachusetts Institute of Technology. \nThe title of this talk will be\, “Accelerating chemical development with automation and machine learning.” \n Register for this virtual event. \n \nMore About Klavs jensen:\nKlavs F. Jensen is Warren K. Lewis Professor in Chemical Engineering and Materials Science and Engineering at the Massachusetts Institute of Technology. From 2007- July 2015 he was the Head of the Department of Chemical Engineering. His research interests include on-demand multistep synthesis\, methods for automated synthesis\, and machine learning techniques for chemical synthesis and interpreting large chemical data sets. He is a co-director of MIT’s consortium\, Machine Learning for Pharmaceutical Discovery and Synthesis\, which aims to bring machine learning technology into pharmaceutical discovery and development. Professor Jensen is a member of the US National Academy of Sciences\, the US National Academy of Engineering as well as the American Academy of Arts and Science. He is a Fellow of the American Association for the Advancement of Science (AAAS)\, and the American Institute of Chemical Engineers\, and the Royal Society of Chemistry. \n Learn more about Klavs Jensen’s lab
URL:https://mbd.ccrm.ca/event/global-speaker-series-klavs-jensen-phd-massachusetts-institute-of-technology/
LOCATION:Ontario
CATEGORIES:Global Speaker Series
ORGANIZER;CN="Medicine by Design":MAILTO:info.mbd@utoronto.ca
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220412T120000
DTEND;TZID=America/Toronto:20220412T130000
DTSTAMP:20260405T130404
CREATED:20220315T134520Z
LAST-MODIFIED:20220327T004408Z
UID:16729-1649764800-1649768400@mbd.ccrm.ca
SUMMARY:Global Speaker Series: Elmar Jaeckel\, MD - University Health Network
DESCRIPTION:The Medicine by Design Global Speaker Series invites established and emerging international leaders in regenerative medicine to engage with our extraordinary community of researchers and clinicians. \nMedicine by Design\, in partnership with the McEwen Stem Cell Institute\, is pleased to welcome Elmar Jaeckel\, MD\, Medical Director at the Liver Transplant Program\, Ajmera Transplant Centre at the University Health Network. \nThe title of this talk will be\, Tissue-specific tolerance by genetically modified regulatory T cells enables endogenous regeneration. \n Register for this virtual event. \nMore About elmar jaeckel:\nDr. Elmar Jaeckel is a trained gastroenterologist/hepatologist as well as endocrinologist/diabetologist and transplantation specialist. He is Medical Director of the Liver Transplant Program at the Transplant Centre\, University Health Network. Dr. Jaeckel studied medicine at University of Hamburg\, Yale University New Haven\, University of California San Diego\, University of Edinburgh and University of Sydney. He completed his medical training at the Hannover Medical School (MHH). He studied medical economics at the University of applied sciences in Hannover and received a bachelor as Medical Hospital Manager. Dr. Jaeckel spent a four years postdoctoral research fellowship with Harald von Boehmer at the Harvard Medical School/Joslin Diabetes Center\, Boston working on central and peripheral tolerance mechanisms in type 1 diabetes. Since 2003\, he has been leading the research group on immune tolerance and metabolic inflammation at the MHH. The group is focusing to establish tissue-specific tolerance in autoimmunity\, transplantation and metabolic inflammation. Since 2008 he is attending for gastroenterology\, hepatology\, endocrinology and diabetology at Hannover Medical School. \nDr. Jaeckel’s working group Immune Tolerance aims in establishing immune tolerance in type 1 diabetes and after biological beta cell replacement. For this purpose\, he is developing new cell and gene therapy approaches. He is involved in pursuing islet xenotransplantation in Germany and to facilitate tolerance to stem cell derived beta cells. One major research focus is the change of specificity of regulatory T cells for beta cells by the use of chimeric antigen-receptors (CARs). In addition\, he aims in local control of immune responses in metabolic inflammation in NASH patients. \nHe was co-chairing the collaborative research center transplantation for 12 years (CRC738)\, the CRC on xenotransplantation (CRC TR127) funded by the German Research Foundation and the Integrated Research Center Transplantation (IFB-Tx) funded by Federal Ministry for research and education. Besides this he received funding from the German Research Foundation\, Ministry of Health\, European Community\, Helmsley Foundation\, Juvenile Diabetes Research Foundation. \nDr. Jaeckel published numerous articles on viral hepatitis\, autoimmune liver disease\, autoimmune diabetes and islet transplantation tolerance. He developed tissue-specific regulatory T cell therapies for local tolerance induction\, which are currently being tested in clinical trials. He has numerous patents on tolerance inducing therapies and is co-founder of Quell Therapeutics aiming to develop clinical therapies for tolerance induction with regulatory T cells.
URL:https://mbd.ccrm.ca/event/global-speaker-series-elmar-jaeckel-phd-university-health-network/
LOCATION:Ontario
CATEGORIES:Global Speaker Series
ORGANIZER;CN="Medicine by Design":MAILTO:info.mbd@utoronto.ca
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220315T120000
DTEND;TZID=America/Toronto:20220315T130000
DTSTAMP:20260405T130404
CREATED:20220208T154825Z
LAST-MODIFIED:20220308T200651Z
UID:16479-1647345600-1647349200@mbd.ccrm.ca
SUMMARY:Global Speaker Series: Anne Brunet\, PhD - Stanford University
DESCRIPTION:The Medicine by Design Global Speaker Series invites established and emerging international leaders in regenerative medicine to engage with our extraordinary community of researchers and clinicians. \nMedicine by Design\, in partnership with the McEwen Stem Cell Institute\, is pleased to welcome Anne Brunet\, PhD\, Professor of Genetics at Stanford University. \nThe title of this talk will be\, Mechanisms of Aging. \n Register for this virtual event. \n \nMore About anne brunet:\nDr. Brunet obtained her B.Sc. from the Ecole Normale Supérieure in Paris and her Ph.D. from the University of Nice\, France. She did her postdoctoral training with Dr. Michael Greenberg at Harvard Medical School. Dr. Brunet is interested in the molecular mechanisms of aging and longevity. She wants to understand the mechanism of neural stem cell aging. She also seeks to discover novel genes regulating longevity\, notably developing a new short-lived vertebrate\, the African killifish. Dr. Brunet has published over 80 peer-reviewed papers and reviews. She has received several awards\, including the Pfizer/AFAR Innovation in Aging Research Award and the Vincent Cristofalo “Rising Star” Award in Aging Research. She received a Pioneer Award and a Transformative Award from the NIH Director’s fund\, which supports scientists who propose pioneering and transforming approaches to major challenges in biomedical research. \n Learn more about Anne Brunet’s lab
URL:https://mbd.ccrm.ca/event/global-speaker-series-anne-brunet-phd-stanford-university/
LOCATION:Ontario
CATEGORIES:Global Speaker Series
ORGANIZER;CN="Medicine by Design":MAILTO:info.mbd@utoronto.ca
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220215T120000
DTEND;TZID=America/Toronto:20220215T130000
DTSTAMP:20260405T130404
CREATED:20220114T175715Z
LAST-MODIFIED:20220519T003652Z
UID:16256-1644926400-1644930000@mbd.ccrm.ca
SUMMARY:Global Speaker Series: Lior Zangi\, PhD - Icahn School of Medicine
DESCRIPTION:The Medicine by Design Global Speaker Series invites established and emerging international leaders in regenerative medicine to engage with our extraordinary community of researchers and clinicians. \nMedicine by Design\, in partnership with the McEwen Stem Cell Institute\, is pleased to welcome Lior Zangi\, PhD\, Associate Professor\, Cardiovascular Research Institute\, Genetics at Icahn School of Medicine. \nThe title of this talk will be\, mRNA-Based Approach for Treating Ischemic Heart Disease. \n Register for this virtual event. \n \nMore About Lior Zangi:\nLior Zangi\, PhD\, is an Associate Professor with Tenure at the Icahn School of Medicine at Mount Sinai\, New York. He completed his education and training at the Weizmann Institute of Science\, and Harvard University. He has established a new method\, mRNA based\, for gene delivery into skeletal and cardiac muscle. In the last year\, these mRNA delivery methods have been used for COVID19 vaccinations and promoting cardiovascular regeneration in ischemic heart disease. Currently\, Prof. Zangi’s laboratory investigates mRNA delivery method into healthy or unhealthy specific cell types and organs\, top fight different diseases such as heart failure and cancer. \n Learn more about Lior Zangi’s lab
URL:https://mbd.ccrm.ca/event/global-speaker-series-lior-zangi-phd-icahn-school-of-medicine/
LOCATION:Ontario
CATEGORIES:Global Speaker Series
ORGANIZER;CN="Medicine by Design":MAILTO:info.mbd@utoronto.ca
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220118T120000
DTEND;TZID=America/Toronto:20220118T130000
DTSTAMP:20260405T130404
CREATED:20211214T213150Z
LAST-MODIFIED:20220117T214918Z
UID:16071-1642507200-1642510800@mbd.ccrm.ca
SUMMARY:Global Speaker Series: Trey Ideker\, PhD - University of California San Diego
DESCRIPTION:The Medicine by Design Global Speaker Series invites established and emerging international leaders in regenerative medicine to engage with our extraordinary community of researchers and clinicians. \nMedicine by Design\, in partnership with the McEwen Stem Cell Institute\, is pleased to welcome Trey Ideker\, PhD\, Professor in the Departments of Medicine\, Bioengineering and Computer Science at UC San Diego. \nThe title of this talk will be\, Building the Mind of Cancer. \n Register for this virtual event. \n \nMore About trey ideker:\nTrey Ideker\, Ph.D. is a Professor in the Departments of Medicine\, Bioengineering and Computer Science at UC San Diego. Additionally\, he is the Director or Co-Director of the National Resource for Network Biology (NRNB)\, the Cancer Cell Map Initiative (CCMI)\, the Psychiatric Cell Map Initiative (PCMI)\, and the UCSD Bioinformatics PhD Program\, and former Chief of Genetics in the Department of Medicine. Dr. Ideker received Bachelor’s and Master’s degrees from MIT in Electrical Engineering and Computer Science and his Ph.D. from the University of Washington in Molecular Biology under the supervision of Dr. Leroy Hood. He currently serves on the Editorial Boards for Cell\, Cell Reports\, Molecular Systems Biology\, and PLoS Computational Biology and is a Fellow of AAAS and AIMBE. He is a member of the Web of Science Highly Cited Researchers list\, reserved each year for the top 1% of scientists by citations. He was named a Top 10 Innovator by Technology Review and was the recipient of the Overton Prize from the International Society for Computational Biology. His work has been featured in news outlets such as NPR\, BBC\, New York Times\, Scientific American\, Smithsonian\, Discover\, Forbes magazine\, Popular Mechanics and People Magazine. \nThe Ideker Laboratory seeks to map the molecular networks governing cancer and neurological disorders and to use these maps in artificially intelligent systems for precision medicine. The laboratory also produces the Cytoscape ecosystem of network analysis tools\, which has been cited over 25\,000 times. \n Learn more about Trey Ideker’s lab
URL:https://mbd.ccrm.ca/event/global-speaker-series-trey-ideker-phd-university-of-california-san-diego/
LOCATION:Ontario
CATEGORIES:Global Speaker Series
ORGANIZER;CN="Medicine by Design":MAILTO:info.mbd@utoronto.ca
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20211116T120000
DTEND;TZID=America/Toronto:20211116T130000
DTSTAMP:20260405T130404
CREATED:20210729T141929Z
LAST-MODIFIED:20211108T163620Z
UID:14767-1637064000-1637067600@mbd.ccrm.ca
SUMMARY:Global Speaker Series: Elly Tanaka\, PhD - Research Institute of Molecular Pathology (IMP)
DESCRIPTION:The Medicine by Design Global Speaker Series invites established and emerging international leaders in regenerative medicine to engage with our extraordinary community of researchers and clinicians. \nMedicine by Design\, in partnership with the McEwen Stem Cell Institute\, is pleased to welcome Elly Tanaka\, PhD\, senior scientist at the Research Institute of Molecular Pathology (IMP) in Vienna\, Austria. \nThe title of this talk will be\, Deciphering the cellular and molecular basis of limb regeneration ability and inability. \n Register for this virtual event. \n \nMore About ELLY TANAKA:\nElly Tanaka is currently a senior scientist at the Research Institute of Molecular Pathology (IMP) in Vienna\, Austria. \nProfessor Tanaka studies the molecular cell biology of limb and spinal cord regeneration as well as the evolution of regeneration. She received her PhD from University of California in San Francisco where she worked with Marc Kirschner in the Department of Biochemistry. She did her post-doctoral research on limb regeneration with Jeremy Brockes at the Ludwig Institute and University College London. \nIn 1999 she moved to the Max-Planck Institute of Molecular Cell Biology and Genetics in Dresden where she started a junior research group working on axolotl spinal cord regeneration. In 2004 she was promoted to associate level. In 2008 she became Chair of the Animal Models of Regeneration in the Center for Regenerative Therapies\, Dresden at the Technische Universität Dresden where she holds an honorary professorship. In 2016 she moved to the Institute of Molecular Pathology as a senior scientist. She has received a number of awards including the Schering Prize\, the Schroedinger Prize and the FEBS EMBO Women in Science Award. \n Learn more about Elly Tanaka’s lab
URL:https://mbd.ccrm.ca/event/global-speaker-series-elly-tanaka-phd/
LOCATION:Ontario
CATEGORIES:Global Speaker Series
ORGANIZER;CN="Medicine by Design":MAILTO:info.mbd@utoronto.ca
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20211019T120000
DTEND;TZID=America/Toronto:20211019T130000
DTSTAMP:20260405T130404
CREATED:20210729T141125Z
LAST-MODIFIED:20210804T141519Z
UID:14762-1634644800-1634648400@mbd.ccrm.ca
SUMMARY:Global Speaker Series: Wilson Wong\, PhD - Boston University
DESCRIPTION:The Medicine by Design Global Speaker Series invites established and emerging international leaders in regenerative medicine to engage with our extraordinary community of researchers and clinicians. \nMedicine by Design\, in partnership with the McEwen Stem Cell Institute\, is pleased to welcome Wilson Wong\, PhD\, Associate Professor in the Department of Biomedical Engineering at Boston University. \nThe title of this talk will be\, Mammalian Cell Design Using Synthetic Biology \n Register for this virtual event. \n \nMore About WILSON WONG:\nWilson Wong is an Associate Professor in the Biomedical Engineering Department at Boston University\, and a core member of the BU Biological Design Center. His lab is focused on developing synthetic biology tools in mammalian systems for cell-based immunotherapy. He received his B.S. degree in Chemical Engineering from UC Berkeley and a Ph.D. degree in Chemical Engineering from UCLA under the guidance from Dr. James Liao. He did his postdoctoral work with Dr. Wendell Lim and Arthur Weiss at UCSF. He is the recipient of the NIH Director’s New Innovator and NSF CAREER Award. \n Learn more about Wilson Wong’s lab
URL:https://mbd.ccrm.ca/event/global-speaker-series-wilson-wong-phd-boston-university/
LOCATION:Ontario
CATEGORIES:Global Speaker Series
ORGANIZER;CN="Medicine by Design":MAILTO:info.mbd@utoronto.ca
END:VEVENT
END:VCALENDAR